Welcome to our dedicated page for Harmony Biosciences Holdings SEC filings (Ticker: HRMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. Harmony Biosciences is a commercial-stage pharmaceutical company focused on rare neurological diseases, and its filings offer detailed insight into financial performance, clinical milestones and strategic developments around its WAKIX (pitolisant) franchise and late-stage CNS pipeline.
Recent Forms 8-K filed by Harmony Biosciences report preliminary and actual financial results, such as net product revenue for WAKIX, multi-quarter revenue growth and updated annual guidance ranges. These filings also incorporate press releases and investor presentations that describe the company’s status as a profitable, self-funding biotech with a robust late-stage pipeline, as well as disclosures tied to participation in major healthcare conferences. For investors analyzing HRMY, these documents help contextualize revenue trends, cash generation and spending on research and development, sales and marketing, and general and administrative activities.
Harmony’s 8-K filings also reference significant clinical and regulatory events, including topline data from the Phase 3 RECONNECT study of ZYN002 in Fragile X syndrome, preannounced WAKIX performance, and updates on Phase 3 and Phase 1 programs such as pitolisant GR, pitolisant HD, EPX-100, EPX-200 and BP1.15205. Through these filings, readers can follow how clinical outcomes, trial initiations and program decisions feed into the company’s overall strategy in sleep–wake disorders, rare epilepsies and neurobehavioral conditions.
On Stock Titan, Harmony Biosciences’ SEC filings are complemented by AI-powered summaries that explain the key points of lengthy documents, including 8-Ks and, when available, 10-K annual reports, 10-Q quarterly reports and proxy materials. Investors can also monitor insider and executive transaction reports on Form 4 and other ownership filings as they appear in the EDGAR feed. This combination of real-time updates and AI-generated explanations helps users quickly understand the implications of HRMY’s regulatory disclosures without reading every page of each filing.
FMR LLC has filed an amended Schedule 13G reporting beneficial ownership of 3,112,812.16 shares of Harmony Biosciences Holdings, Inc. common stock, representing 5.4% of the class as of the reporting date.
FMR LLC reports sole voting power over 3,109,042 shares and sole dispositive power over 3,112,812.16 shares, with no shared voting or dispositive power. Abigail P. Johnson is also listed as a reporting person with sole dispositive power over 3,112,812.16 shares and no voting power. The filers certify the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of Harmony Biosciences.
Harmony Biosciences Holdings, Inc. disclosed that Chief Financial Officer Sandip Kapadia sold 3,746 shares of common stock on January 26, 2026 in an open-market transaction coded as a sale. The shares were sold at a weighted average price of $37.152 under a pre-arranged Rule 10b5-1 trading plan.
After this transaction, Kapadia directly beneficially owned 24,521 shares of Harmony Biosciences common stock. The filing also notes that a previous Form 4 filed on January 26, 2026 had inadvertently misstated the post-transaction share balance, which has been corrected in this report.
Harmony Biosciences Holdings, Inc. chief financial officer Sandip Kapadia reported several equity compensation transactions. On January 22, 2026, he received a stock option for 42,600 shares of common stock at an exercise price of $36.76, and 12,200 restricted stock units (RSUs), both vesting over multiple years subject to continued service.
On January 24, 2026, 3,813 RSUs previously granted on January 24, 2024 vested and converted into the same number of common shares. Of these, 2,239 shares were withheld at $36.82 per share to cover taxes, leaving 1,574 shares of common stock directly held. On January 25, 2026, 4,725 RSUs from a January 25, 2025 grant vested, with 2,553 shares withheld for taxes at $36.82 per share and 2,172 shares retained as common stock.
Harmony Biosciences Chief Strategy Officer Andrew Serafin reported multiple equity compensation transactions and related tax withholdings. On January 22, 2026, he received a stock option for 42,600 shares of common stock at an exercise price of
Harmony Biosciences (HRMY) chief medical officer Budur Kumar reported new equity awards and routine tax withholding transactions. On January 22, 2026, Kumar received a stock option for 42,600 shares of common stock at an exercise price of $36.76, vesting 25% on January 22, 2027 with the remainder vesting quarterly until the fourth anniversary, subject to continued service. On the same date, Kumar was granted 12,200 restricted stock units (RSUs) that vest in four equal annual installments beginning January 22, 2027.
On January 24 and 25, 2026, portions of earlier RSU grants vested, converting 2,188 and 2,662 RSUs into common shares. The company withheld 1,153 and 1,372 shares, respectively, at a price of $36.82 per share to satisfy income tax obligations, leaving 1,035 and 1,290 shares directly held after each event.
Harmony Biosciences Holdings, Inc.
The option vests 25% on January 22, 2027, with the remaining shares vesting quarterly until the fourth anniversary of the grant date, subject to continued service. On the same date, Zaeske was also granted 16,200 restricted stock units, which vest in four equal annual installments beginning January 22, 2027, each representing one share of common stock.
Harmony Biosciences Holdings, Inc.January 22, 2026, he received a stock option for 184,600 shares of common stock at an exercise price of $36.76, vesting 25% on January 22, 2027 and the rest quarterly until the fourth anniversary of the grant. He was also granted 52,900 restricted stock units (RSUs) that vest in four equal annual installments beginning January 22, 2027.
On January 24, 2026, 10,500 shares of common stock were issued upon vesting of previously granted RSUs, and 4,785 shares were withheld at $36.82 per share to satisfy tax obligations, leaving 5,715 shares held directly. On January 25, 2026, an additional 13,000 shares were issued from RSU vesting, with 5,654 shares withheld at $36.82 for taxes, leaving 7,346 shares held directly.
A holder has filed a notice to sell 3,746 shares of Harmony Biosciences common stock (HRMY). The planned sale is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services on or around 01/26/2026 on the NASDAQ market. These shares come from restricted stock units acquired from the issuer on 01/24/2026.
The notice also lists recent activity under a Rule 10b5-1 trading plan for Sandip Kapadia. Over the past three months, there were sales of 20,961 shares for $752,833.18 on 01/15/2026, 20,000 shares for $790,896.00 on 12/05/2025, and 3,427 shares for $119,945.00 on 11/21/2025. The filer represents that they are not aware of undisclosed material adverse information about Harmony Biosciences.
Harmony Biosciences Holdings, Inc. reported an insider sale by its chief financial officer, Sandip Kapadia. On January 15, 2026, Kapadia sold 20,961 shares of Harmony Biosciences common stock in an open-market transaction coded as a sale. The filing states that these sales were made under a pre-established Rule 10b5-1 trading plan, which is designed to allow insiders to trade according to a preset schedule. The weighted average sale price was $35.9159 per share, with individual trades executed between $35.68 and $36.10. After this transaction, the Form 4 reports that Kapadia directly beneficially owned 0 shares of the company’s common stock.
An affiliate of HRMY has filed a Rule 144 notice to sell up to 20,961 shares of common stock, with an aggregate market value of
Over the past three months, sales labeled as 10b5-1 sales for Sandip Kapadia included 20,000 common shares on